Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

• Status: Completed
• Trial end date: 2017-01-13

Summary

This is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.

• Phase: Phase 1

Details

• Lead Sponsor: Santa Maria Biotherapeutics
• Treatments: Doxorubicin; Liposomal doxorubicin